Source: www.law360.com – Read more

StockWatch: Cosmo Surges 40% on Baldness Candidate’s Phase III Data
Cosmo Pharmaceuticals (SIX Swiss: COSM) found itself this past week in the enviable position of attracting welcome attention from investors and other market watchers after


